Ionis Pharmaceuticals
olezarsen
severe hypertriglyceridemia
Resolved
7days ago
FDA decision · Jun 30, 2026
What's at stake
The FDA's approval decision on olezarsen for severe hypertriglyceridemia is due Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“Potential approval and launch of olezarsen as the new standard of care for severe hypertriglyceridemia (sHTG) o Submitted U.S. Supplemental New Drug Application (sNDA), following receipt of Breakthrough Therapy Designation”